What is B. Riley’s Forecast for NKTR FY2024 Earnings?

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at B. Riley issued their FY2024 earnings estimates for Nektar Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will earn ($0.83) per share for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. B. Riley also issued estimates for Nektar Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.65) EPS.

Several other analysts have also issued reports on NKTR. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research note on Monday, September 30th. HC Wainwright initiated coverage on shares of Nektar Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $6.50 target price for the company. Finally, Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price for the company. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.08.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $1.03 on Friday. Nektar Therapeutics has a 1 year low of $0.48 and a 1 year high of $1.93. The firm has a market cap of $189.99 million, a price-to-earnings ratio of -1.23 and a beta of 0.59. The company has a fifty day moving average price of $1.08 and a 200-day moving average price of $1.21.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of NKTR. Bank of New York Mellon Corp lifted its holdings in shares of Nektar Therapeutics by 2,822.5% in the second quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 532,663 shares in the last quarter. Rhumbline Advisers raised its stake in Nektar Therapeutics by 3,377.0% in the second quarter. Rhumbline Advisers now owns 185,116 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 179,792 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Nektar Therapeutics in the second quarter valued at approximately $29,000. Candriam S.C.A. purchased a new stake in Nektar Therapeutics in the second quarter valued at approximately $99,000. Finally, Samlyn Capital LLC purchased a new stake in Nektar Therapeutics in the second quarter valued at approximately $11,728,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 46,995 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the sale, the chief executive officer now directly owns 1,195,710 shares of the company’s stock, valued at $1,207,667.10. This represents a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Andrew Wilson sold 33,402 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the sale, the insider now directly owns 351,892 shares in the company, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 155,575 shares of company stock worth $149,878. 3.71% of the stock is owned by company insiders.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.